The Drug Enforcement Administration (DEA) has finalized quotas for legal production of controlled substances in 2026—further raising the amount of certain psychedelics that can be made for research purposes in the new year.
In a notice published in the Federal Register on Monday, DEA increased its quotas for psilocybin, psilocyn and DMT compared to what the agency proposed in its draft rule in November.
DEA said in its initial proposal that it was moving to boost the quotas for the psychedelics substances so researchers can study whether they could serve as “potential treatment of conditions such as post-traumatic stress disorder (PTSD) and depression.”
Based on public comments the agency received, it said the amounts were adjusted to be “at higher levels than were proposed,” without expanding on the specific rationale for the individual quota increases.
The production goal for psilocybin rose from 30,000 grams last year to 40,000 grams in the initial rule for this year—and has now been raised to 50,000 grams in 2026’s final rule.
The psilocyn quota increased from 36,000 grams in 2025 to 48,000 grams in the initial 2026 rule before being raised again to 80,000 grams in the final rule for 2026—more than doubling in
Read full article on Marijuana Moment
